How improvements in US FDA regulatory process and procedures led to the drug approval for first ever treatment of a common liver disease
Crossref DOI link: https://doi.org/10.1038/s41401-024-01396-4
Published Online: 2024-11-07
Published Print: 2025-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Harvey, Brian E.
Text and Data Mining valid from 2024-11-07
Version of Record valid from 2024-11-07
Article History
Received: 9 June 2024
Accepted: 13 September 2024
First Online: 7 November 2024
Competing interests
: The author declares no competing interests.